RecruitingPhase 2NCT05664737
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
Studying Alpha-thalassemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- Luspatercept(biological)
- Enrollment
- 189 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2022 – 2034
Study locations (30)
- Local Institution - 0008, Halifax, Nova Scotia, Canada
- Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, GD, China
- Nanfang Hospital of Southern Medical University, Guangzhou, GD, China
- The First People's Hospital of Foshan, Foshan, Guangdong, China
- Maoming People's Hospital, Maoming Shi, Guangdong, China
- Shenzhen Second People's Hospital, Shenzhen Shi, Guangdong, China
- Liuzhou People's Hospital, Liuchow, Guangxi, China
- People's Liberation Army The 923rd Hospital, Nanning, GX, China
- Local Institution - 0011, Haikou, Hainan, China
- Local Institution - 0012, Kunming, Yunnan, China
- Hainan General Hospital, Haikou, China
- The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Local Institution - 0005, Thessaloniki, B, Greece
- Local Institution - 0007, Larissa, E, Greece
- Local Institution - 0018, Rio, G, Greece
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05664737 on ClinicalTrials.govOther trials for Alpha-thalassemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06591936Genetic Profile of Alpha Thalassemia Children at Sohag University Hospital .Sohag University
- RECRUITINGNANCT06539169FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare DiseasesxCures
- RECRUITINGEARLY PHASE1NCT06107400Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring DiseaseThe 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
- ACTIVE NOT RECRUITINGPHASE3NCT04770753A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)Agios Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE3NCT04770779A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Agios Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGNANCT02692872Screening for Alpha Thalassemia in Healthy VolunteersNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT04872179International Registry of Patients With Alpha ThalassemiaUniversity of California, San Francisco